In conjunction with the Bioshares Biotech Summit

Radiopharm Theranostics (ASX: RAD)

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases.

Paradigm Biopharma (ASX: PAR)

Paradigm Biopharmaceuticals is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

Bioxyne (ASX: BXN)

Bioxyne is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

Chimeric Therapeutics (ASX: CHM)

Chimeric Therapeutics is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric’s assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

ImmVirX (Private)

ImmVirX is developing novel oncolytic immunotherapies to create powerful new cancer therapy combinations. Its lead asset, IVX037, is in clinical studies and its second agent, IVX055, is scheduled to enter the clinic in mid-2026. The Company’s novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce local and systemic anti-tumor immune responses. The proprietary bio-selection platform enables the development of RNA viruses targeting specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumor cells while creating beneficial changes in the tumor micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.

Avecho Biotechnology (ASX: AVE)

Avecho Biotechnology develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia, with interim analysis results expected June 2026.

Emyria (ASX: EMD)

Emyria develops and delivers new treatments for mental health and select neurological conditions through an integrated model combining direct clinical services and treatment development. Its clinical services arm, Emyria Healthcare, provides evidence-based care for patients who have not found relief through conventional treatments while also helping evaluate emerging therapies such as assisted therapies for PTSD and treatment-resistant depression. The Company’s Emyria Data platform generates robust, ethically sourced real-world data from these patients, which in turn informs and strengthens the development of new treatments. This data feeds into Emyria’s pipeline, which is focused on advancing psychedelic-assisted therapies and novel drug treatments for mental health and select neurological diseases.

Alterity Therapeutics (ASX: ATH)

Alterity Therapeutics is a late clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases. Its lead candidate, ATH434, is an oral small molecule designed to restore brain iron balance and inhibit the aggregation of pathological proteins implicated in neurodegeneration. In a randomized, placebo-controlled Phase 2 trial in Multiple System Atrophy (MSA), a rare, rapidly progressive Parkinsonian disorder with no approved disease-modifying treatments, ATH434 demonstrated clinically meaningful efficacy, target engagement, and a favourable safety and tolerability profile. ATH434 has received U.S. FDA Fast Track designation and Orphan Drug designation for MSA, as well as Orphan Drug designation in Europe.

Neurotech International (ASX: NTI)

Neurotech International is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double- blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

Syntara (ASX: SNT)

Syntara is a clinical-stage biotechnology company developing novel medicines targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead drug candidate, amsulostat (SNT-5505), is being developed for the bone marrow cancer myelofibrosis and has received FDA Fast Track and Orphan Drug Designations, with a Phase 2a trial completed and additional studies underway in myelodysplastic syndrome. The company is also advancing other programs targeting fibrosis and inflammation, including SNT-9465 for hypertrophic scars, SNT-6302 for keloid scars in collaboration with the University of Western Australia, and SNT-4728 being studied with Parkinson’s UK for neuroinflammation-related sleep disorders and neurodegenerative diseases such as Parkinson’s.

EMVision (ASX: EMV)

EMVision is an innovative Australian medical device company whose mission is to become a leading global medical imaging provider. EMV is reducing the global burden of stroke and traumatic brain injury through the deployment of two world-first portable brain scanning devices. Its flagship brain scanner technology stems from more than a decade of research and development at The University of Queensland. The company’s vision is to transform the stroke care paradigm and improve outcomes for millions of people worldwide by delivering a portable, cost-effective, non-ionising, and safe brain scanners. EMVision has strong foundational clinical data, including a 300-patient pre-validation study showing high accuracy. The company is now advancing its pivotal (validation) trial for the emu™, a multi-center, blinded study focused on detecting intracranial hemorrhage in suspected stroke patients vs standard neuroimaging (CT/MRI) to support FDA De Novo clearance.

Filamon (Private)

Filamon is an Australian, public, unlisted drug development company focused on the development of next generation anti-inflammatory drugs for age-related chronic inflammatory diseases. The target is degenerative diseases accounting for most hospitalisations and deaths in developed countries. The target indications are solid cancers, ophthalmic diseases including wet AMD and dry AMD, and neurological diseases associated with neuroinflammation. The Company’s focus is on providing the aging population with a renewed chance for more productive and independent living. Through groundbreaking research and technology, we are reshaping what it means to treat age-related chronic diseases.

Nexalis Therapeutics (ASX: NX1)

Nexalis Therapeutics is an Australian Clinical Stage Drug Development Company that is developing rapid onset therapies to address unmet medical needs in pain management and mental health sectors. The Company has secured a funding partner with a facility of up to $52.3m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain (‘BTcP’), IRX-616a to treat Panic Disorder (‘PD’) and SRX-25 for the treatment of Treatment-Resistant Depression (‘TRD’). The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

Saluda Medical (ASX: SLD)

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company’s closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company’s first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden.

Vitrafy (ASX: VFY)

Vitrafy Life Sciences is developing a cryopreservation ecosystem (the process of freezing and storing biological materials used in cell and gene therapies, blood products, and medical research). Cryopreservation is a $57.6 billion global industry built on technology that hasn’t meaningfully evolved since the 1960s, leaving it poorly integrated into modern clinical workflows. Vitrafy addresses this gap with an integrated ecosystem: the Guardion™ controlled rate freezing device, LifeChain™ orchestration software, and a fully managed service model. Earlier this year, the company announced a commercial partnership with IMV Technologies (holds approximately 50% of the global animal reproduction market) while continuing to build its commercial capabilities in US human health markets.

Fund Manager Q&A – Emerging Trends

Firebrick Pharma (ASX: FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine ® Throat Spray is the first follow-on product, now available in Singapore and Fiji.

PainChek (ASX: PCK)

PainChek® is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates. The PainChek ® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek ® Analytics. Globally, PainChek ® has attained regulatory clearance as a medical device in Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom

Tetratherix (ASX: TTX)

Tetratherix has developed a proprietary fluid matrix that is invisible to the body and does not induce any foreign body reaction to evolve regenerative medicine and targeted therapeutic delivery. Tetramatrix is a water based polymer solution that forms an adhesive hydrogel once administered to the body. The product is fully synthetic, biocompatible and resorbable. After a decade of development with meticulous polymer programing, Tetratherix is advancing the world of biopolymers by developing real world applications specific to multiple indications in an effort to change the lives of patients around the world.

ReNerve (ASX: RNV)

ReNerve is transforming nerve repair and improving lives through breakthrough medicalctechnology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide. ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference in surgical outcomes across the United States.

ECS Botanics (ASX: ECS)

ECS Botanics is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis

Bio-Gene Technology (ASX: BGT)

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment. Bio-Gene’s products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

AnteoTech (ASX: ADO)

AnteoTech develops advanced materials that support next-generation diagnostics, vaccines and biotechnology applications. Its AnteoBind™ product suite enables the activation and binding of biomolecules used in diagnostic tests, delivering more sensitive, reliable and reproducible results across a range of immunoassay and point of care platforms. Using the same proprietary binding chemistry platform, AnteoTech also develops advanced battery materials including Anteo X™ cross linkers and Ultranode™ silicon anode formulations for high performance lithium ion batteries.

InteliCare (ASX: ICR)

InteliCare is an Australian technology company that has commercialised a predictive analytics hardware and software system for use in the aged care and health industries. InteliCare believes Australians deserve to age with dignity and through its business-to-business (B2B) and business-to-consumer (B2C) solutions built on its proprietary internet of things (IOT) platform utilising smart sensors and artificial intelligence (AI), InteliCare aims to enable people to stay in their own homes for longer while empowering healthcare providers to deliver higher quality, more efficient services.

CurveBeam AI (ASX: CVB)

CurveBeam AI develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company’s flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

The Pulse Check: Biotech State of Play in 2026